The Arcadia Trial of the Shearsi Sub

The Arcadia trial was focusing on patients with embolic stroke of unknown source, but they were also required to have so-called atrial cardiopathy. Unfortunately, the study was stopped early and there was no definite benefit seen of a pixoban over aspirin. In fact, both groups had exactly the same number of recurrent strokes at about 4.4% per year. It's sort of back to the drawing board for the concept of ESIS and whether we should retain it in future trials or whether we should focus more on specific entities. We will continue to look for other opportunities and phenotypes to augment our medical therapy going forward.